View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2016	Aug. 03, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Entity Registrant Name	FLAMEL TECHNOLOGIES SA
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	FLML
Entity Common Stock, Shares Outstanding		41,241,254

CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Product sales and services	$ 38,165	$ 48,602	$ 73,518	$ 81,128
License and research revenue	693	0	1,556	0
Total	38,858	48,602	75,074	81,128
Operating expenses:
Cost of products and services sold (excluding intangible asset amortization below)	3,907	2,756	7,813	6,386
Research and development expenses	7,604	7,204	12,992	13,226
Selling, general and administrative expenses	11,290	5,873	20,751	10,336
Intangible asset amortization	3,702	3,139	7,216	6,282
Changes in fair value of related party contingent consideration	23,898	32,000	32,141	37,254
Total	50,401	50,972	80,913	73,484
Operating income (loss)	(11,543)	(2,370)	(5,839)	7,644
Investment income, net	390	310	590	974
Interest expense, net	(263)	0	(438)	0
Other expense - changes in fair value of related party payable	(2,773)	(2,726)	(4,307)	(2,985)
Foreign exchange gain (loss)	1,680	(3,565)	(1,261)	7,936
Income (loss) before income taxes	(12,509)	(8,351)	(11,255)	13,569
Income tax provision	7,449	8,507	14,761	17,214
Net loss	$ (19,958)	$ (16,858)	$ (26,016)	$ (3,645)
Earnings (loss) per share
Net loss per share - basic	$ (0.48)	$ (0.42)	$ (0.63)	$ (0.09)
Net loss per share - diluted	$ (0.48)	$ (0.42)	$ (0.63)	$ (0.09)
Weighted average number of shares outstanding - basic	41,241	40,353	41,241	40,281
Weighted average number of shares outstanding - diluted	41,241	40,353	41,241	40,281

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net loss	$ (19,958)	$ (16,858)	$ (26,016)	$ (3,645)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	(2,457)	5,262	2,360	(11,387)
Unrealized gain (loss) on marketable securities, net of ($73), $0, ($158), $0 tax	528	(356)	1,447	0
Total other comprehensive income (loss), net of tax	(1,929)	4,906	3,807	(11,387)
Total comprehensive loss	$ (21,887)	$ (11,952)	$ (22,209)	$ (15,032)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	$ (73)	$ 0	$ (158)	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 23,899	$ 65,064
Marketable securities	130,964	79,738
Accounts receivable (net of allowance of $35 at both June 30, 2016 and December 31, 2015)	9,488	7,487
Inventories	3,640	3,666
Research and development tax credit receivable	0	2,382
Prepaid expenses and other current assets	9,657	8,064
Total current assets	177,648	166,401
Property and equipment, net	3,104	2,616
Goodwill	18,669	18,491
Intangible assets, net	29,209	15,825
Research and development tax credit receivable	4,034	0
Income tax deferred charge	11,381	11,581
Other	5,661	167
Total assets	249,706	215,081
Current liabilities:
Current portion of long-term debt	283	434
Current portion of long-term related party payable	29,500	25,204
Accounts payable	7,043	5,048
Deferred revenue	3,820	5,121
Accrued expenses	10,592	9,308
Income taxes	6,286	0
Other	664	133
Total current liabilities	58,188	45,248
Long-term debt, less current portion	788	684
Long-term related party payable, less current portion	136,021	97,489
Other	2,871	2,526
Total liabilities	197,868	145,947
Shareholders' equity:
Ordinary shares, nominal value of 0.122 euro per share; 53,178 shares authorized; 41,241 issued and outstanding at June 30, 2016 and December 31, 2015	6,331	6,331
Additional paid-in capital	368,897	363,984
Accumulated deficit	(304,540)	(278,524)
Accumulated other comprehensive loss	(18,850)	(22,657)
Total shareholders' equity	51,838	69,134
Total liabilities and shareholders' equity	$ 249,706	$ 215,081

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] shares in Thousands, $ in Thousands	Jun. 30, 2016 USD ($) shares	Jun. 30, 2016 € / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 € / shares
Allowance for accounts receivable (in dollars) \| $	$ 35		$ 35
Common stock, par value (in euro per share) \| € / shares		€ 0.122		€ 0.122
Common stock, shares authorized	53,178		53,178
Common stock, shares issued	41,241		41,241
Common stock, shares outstanding	41,241		41,241

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (26,016)	$ (3,645)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	7,681	6,531
Loss on disposal of property and equipment	110	0
Loss on sale of marketable securities	455	225
Unrealized exchange loss (gain)	1,261	(7,315)
Grants recognized in research and development expenses and operating income	(70)	(1,086)
Remeasurement of related party acquisition-related contingent consideration	32,141	37,254
Remeasurement of related party financing-related contingent consideration	4,307	2,985
Change in deferred tax and income tax deferred charge	(5,028)	3,442
Stock-based compensation expense	4,913	4,152
Increase (decrease) in cash from:
Accounts receivable	(1,689)	467
Inventories	2,345	1,175
Prepaid expenses and other current assets	546	(1,876)
Research and development tax credit receivable	(1,630)	3,807
Accounts payable & other current liabilities	(348)	2,194
Deferred revenue	(1,461)	(1,314)
Accrued expenses	777	(614)
Accrued income taxes	6,285	(7,636)
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(7,769)	0
Royalty payments for related party payable in excess of original fair value	(1,159)	0
Other long-term assets and liabilities	270	555
Net cash provided by operating activities	15,921	39,301
Cash flows from investing activities:
Purchases of property and equipment	(760)	(659)
Acquisitions of businesses	161	0
Proceeds from sales of marketable securities	26,013	21,196
Purchase of marketable securities	(75,528)	(31,093)
Net cash used in investing activities	(50,114)	(10,556)
Cash flows from financing activities:
Earn-out payments for related party contingent consideration	(6,572)	(6,118)
Royalty payments for related party payable	(816)	(888)
Repayment of debt	0	(4,903)
Reimbursement of conditional grants	0	(615)
Cash proceeds from issuance of ordinary shares and warrants	0	1,652
Net cash used in financing activities	(7,388)	(10,872)
Effect of exchange rate changes on cash and cash equivalents	416	(2,397)
Net increase (decrease) in cash and cash equivalents	(41,165)	15,476
Cash and cash equivalents at January 1	65,064	39,760
Cash and cash equivalents at June 30	$ 23,899	$ 55,236

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 : Summary of Significant Accounting Policies

Nature of Operations. Flamel Technologies S.A. (“Flamel,” the “Company,” “we” or “us”) is organized as a Société Anonyme, a form of corporation under the laws of The Republic of France. The Company was founded in 1990. Flamel is a specialty pharmaceutical company utilizing core competencies in drug delivery and formulation development to create safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs. The Company has a business model consisting of:

⋅

an Unapproved Marketed Drugs (“UMDs”) business with two approved products in the United States, Bloxiverz^® (neostigmine methylsulfate injection) and Vazculep^® (phenylephrine hydrochloride injection) that are currently marketed, a third product, Akovaz® (ephedrine sulphate injection) for which we obtained FDA approval on April 29, 2016 and which we intend to begin marketing in the third quarter of 2016, and a fourth product currently being studied by us for possible submission for review by the FDA. The UMD business was obtained through the acquisition of Éclat Pharmaceuticals, LLC’s (or “Éclat”) on March 13, 2012,

⋅

a branded pediatric specialty pharmaceutical business, with three FDA approved products and one FDA approved medical device, acquired through the acquisition of FSC Laboratories and FSC Pediatrics (“FSC”) on February 5, 2016; and

⋅

a branded business, focusing on the development of products utilizing Flamel’s proprietary drug delivery platforms. The branded products that are based on Flamel’s proprietary drug delivery platforms target high-value solid and liquid oral and alternative dosage forms using 505(b)(2) and Biosimilar pathways where the Company is able to develop strong intellectual property positions and deliver meaningful patient benefits.

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri, United States, and Dublin, Ireland.

Proposed Reincorporation as an Irish Public Limited Company (plc). At our shareholders meeting on August 10, 2016, our shareholders approved resolutions to change our jurisdiction of incorporation from France to Ireland. Based on such approval, we intend to give effect to this reincorporation on December 31, 2016 by merging with and into our wholly owned Irish corporate subsidiary, Avadel Pharmaceuticals Limited (the “Merger”). Prior to completing the Merger, Avadel Pharmaceuticals Limited will re-register as an Irish public limited company, or plc, and at the time of the Merger and thereafter our shareholders (and holders of our American Depositary Shares (ADSs)) will own shares (or ADSs, as applicable) in a company known as Avadel Pharmaceuticals plc. Our definitive proxy statement filed with the Securities and Exchange Commission on July 5, 2016 contains additional information about the proposed reincorporation.

Basis of Presentation. The Condensed Consolidated Balance Sheet as of December 31, 2015, which is derived from the prior year 2015 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2015 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2016.

The unaudited condensed consolidated financial statements include the accounts of the Company, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.

Foreign Currency Translation. The reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Each of the Company's non-U.S. subsidiaries and the parent entity uses local currency as their functional currency. Subsidiaries and entities that do not use the U.S. dollar as their functional currency translate 1) profit and loss accounts at the weighted average exchange rates during the reporting period, 2) assets and liabilities at period end exchange rates and 3) shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of shareholders' equity in Accumulated Other Comprehensive Loss. Assets and liabilities denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates. Resulting gains and losses are recognized in the Condensed Consolidated Statements of Loss.

Reclassifications and Immaterial Corrections of Prior Period Amounts. The accompanying condensed consolidated financial statements for prior periods contain certain reclassifications to conform to the presentation used in 2016. Additionally, the Company has identified certain immaterial errors related to prior reporting periods. The Company has assessed the impact of the errors on its prior period financial statements included in our December 31, 2015 Annual Report on Form 10-K and concluded that the errors were not material to those financial statements.

Although the effect of the errors was not material to any previously issued financial statements, the cumulative effect of correcting the errors would have been material for the period ended June 30, 2016.

Consequently, the Company has presented the effects of these errors and reclassifications on its prior period financial statements in the tables below. In future filings the financial statements for comparative periods affected by these errors and reclassifications will be revised.

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:

	Three Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			As revised

Product sales and services	$	49,795		$	-		$	-		$	(1,193	)	$	48,602
Total revenue		49,795			-			-			(1,193	)		48,602
Operating income (loss)		(1,177	)		-			-			(1,193	)		(2,370	)
Income (loss) before income taxes		(7,158	)		-			-			(1,193	)		(8,351	)
Income tax provision		10,242			(292	)		(1,026	)		(417	)		8,507
Net loss		(17,400	)		292			1,026			(776	)		(16,858	)
Net loss per share - basic	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)
Net loss per share - diluted	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)

	Six Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	82,521		$	-		$	-		$	(1,193	)	$	(200	)	$	81,128
Total revenue		82,521			-			-			(1,193	)		(200	)		81,128
Operating income (loss)		9,037			-			-			(1,193	)		(200	)		7,644
Income (loss) before income taxes		14,962			-			-			(1,193	)		(200	)		13,569
Income tax provision		20,715			(1,158	)		(1,856	)		(417	)		(70	)		17,214
Net loss		(5,753	)		1,158			1,856			(776	)		(130	)		(3,645	)
Net loss per share - basic	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)
Net loss per share - diluted	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)

	December 31, 2015
				*Correction of Immaterial Errors*									*Reclassifications*
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	-		$	-		$	-		$	509		$	-	$	7,487
Inventories		4,155			-			(489	)		-			-			-		3,666
Prepaid expenses and other current assets		7,989			-			-			-			-			75		8,064
Total current assets		166,306			-			(489	)		-			509			75		166,401
Other		158			-			-			-			-			9		167
Total assets		214,977			-			(489	)		-			509			84		215,081
Current portion of long-term related party payable		28,614			-			-			(3,410	)		-			-		25,204
Accounts payable		10,565			-			-			-			(5,517	)		-		5,048
Accrued expenses		3,598			-			-			-			5,710			-		9,308
Income taxes		323			(227	)		(171	)		-			-			75		-
Total current liabilities		48,788			(227	)		(171	)		(3,410	)		193			75		45,248
Long-term related party payable, less current portion		94,079			-			-			3,410			-			-		97,489
Deferred taxes		1,351			(1,360	)		-			-			-			9		-
Other		2,210			-			-			-			316			-		2,526
Total liabilities		147,112			(1,587	)		(171	)		-			509			84		145,947
Accumulated deficit		(279,793	)		1,587			(318	)		-			-			-		(278,524	)
Total shareholders' equity		67,865			1,587			(318	)		-			-			-		69,134
Total liabilities and shareholders' equity		214,977			-			(489	)		-			509			84		215,081

(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)	Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(c)	Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014.

(d)	Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.

(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.

(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

In addition to the specific amounts identified within the tables above, the Company also changed the names of the previously-reported “Interest expense – changes in fair value of related party financing related contingent consideration” line on the condensed consolidated statement of income (loss) to “Other expense – changes in fair value of related party payable”, and the previously-reported “Long-term related party contingent consideration payable” line on the condensed consolidated balance sheet to “Long-term related party payable” to better reflect the underlying nature of certain royalty agreements in prior periods.

While the balance sheet revisions and reclassifications noted in the tables above impact their corresponding captions within the cash flows provided by (used in) operating activities section of the Company’s consolidated statements of cash flows in each period of 2015, there was no impact to the total net cash provided by (used in) operating activities in any of these periods.

Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, milestone payments for R&D achievements, and compensation for the execution of R&D activities.

Product Sales and Services

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

For generic products and branded products sold in mature markets where the ultimate net selling price to customer is estimable, the Company recognizes revenues upon shipment to the wholesaler. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels.

Prior to the second quarter 2016, the Company did not have sufficient historical data to estimate certain revenue deductions. As such, it could not accurately estimate the ultimate net selling price of its Éclat portfolio of products and as a result delayed revenue recognition until the wholesaler sold the product through to its customers.

During the second quarter of 2016, the Company determined that it has sufficient evidence, history, data and internal controls to estimate the ultimate selling price of its products upon shipment from its warehouse to its customers, the wholesalers. Accordingly, it discontinued the sell through revenue approach and now recognizes revenue once the product is shipped from its warehouse. As a result of this change in accounting estimate, the Company recognized $5,981 in additional revenue, or $0.05 in additional diluted net earnings (loss) per share, for the three and six months ended June 30, 2016 that previously would have been deferred until sold by the wholesalers to the hospitals.

License and Research Revenue

The Company’s license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over our projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured.

Newly Issued Accounting Pronouncements

6 Months Ended

Jun. 30, 2016

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

NOTE 2 : Newly Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU 2016-10 “Identifying Performance Obligations and Licensing,” and ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of its adoption on its condensed consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” which amends Accounting Standards Codification (“ASC”) Topic 718 “Compensation – Stock Compensation”. This update simplifies several aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, classification of awards as either equity or liabilities and classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016. The Company does not believe this standard will materially impact its condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02 “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on its condensed consolidated financial statements.

In September 2015, the FASB issued ASU 2015-16 “Business Combinations” which requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU is effective for interim and annual reporting periods beginning after December 15, 2016, with the option to early adopt for financial statements that have not been issued. The Company early adopted the provisions of ASU 2015-16 for the year ended December 31, 2015 on a prospective basis.

In July 2015, the FASB issued ASU 2015-11 “Simplifying the Measurement of Inventory”, which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016, which for the Company is January 1, 2017. Early adoption is permitted. The new standard is to be applied prospectively. The Company does not expect ASU 2015-11 to have a material impact on its condensed consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Marketable Securities

6 Months Ended

Jun. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Cash Cash Equivalents And Marketable Securities [Text Block]

NOTE 3 : Marketable Securities

The Company has investments in available-for-sale marketable equity securities which are recorded at fair market value and measured using quoted prices in their respective active market, thus representing a level 1 fair value measurement as defined in ASC 820. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects.

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:

	June 30,		December 31,
Marketable Securities:	2016		2015

Value at cost	$	131,041	$	81,395
Gross unrealized holding gains		1,236		15
Gross unrealized holding losses		(1,313)		(1,672)
Fair value	$	130,964	$	79,738

Inventories

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

NOTE 4 : Inventories

The principal categories of inventories at June 30, 2016 and December 31, 2015 are as follows:

	June 30,		December 31,
Inventory:	2016		2015

Finished Goods	$	3,280	$	2,545
Raw Materials		360		1,121
Total	$	3,640	$	3,666

Acquisitions

6 Months Ended

Jun. 30, 2016

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

NOTE 5 : Acquisitions

On February 5, 2016, the Company completed its acquisition of FSC Holdings, LLC (“FSC”), a Charlotte, North Carolina-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients, from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a related party.

This acquisition has been accounted for using the acquisition method of accounting and, accordingly, its results are included in the Company's condensed consolidated financial statements from the date of acquisition. Total consideration to acquire FSC is estimated to be $22,228, and was funded with a combination of the following, partially offset by $467 as a result of a net working capital settlement due from the seller:

⋅

$15,000 long-term liability to Deerfield. Under the terms of the acquisition agreement, the Company will pay $1,050 annually for five years with a final payment in January 2021 of $15,000.

⋅

$7,695 contingent consideration to Deerfield. Under the terms of the acquisition agreement, the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

The present value of these estimated discounted future cash flows for each of these items is reported in related party payable within the Company’s Condensed Consolidated Balance Sheet, and is further disclosed at Note 7 – Long-Term Related Party Payable.

During the first half of 2016, the Company determined its preliminary accounting for the FSC acquisition. As the Company completes its final accounting for the acquisition, future adjustments related to working capital, amortizable intangible assets, goodwill and deferred taxes could occur. The preliminary fair values assigned to the acquired assets and liabilities have been recognized as follows:

Assigned Fair Value:	2016 Preliminary

Accounts receivable	$	825
Inventories		2,315
Prepaid expenses and other current assets		1,712
Goodwill		178
Intangible assets:
Acquired product marketing rights		16,200
Acquired developed technology		4,400
Other assets		392
Accounts payable and other current liabilities		(3,794)
Total	$	22,228

Goodwill resulting from the acquisition is largely attributable to the existing workforce of FSC, and is not expected to be deductible for tax purposes. Transaction expenses for legal and professional fees associated with the acquisition of FSC amounted to $76 during the three and six month period ended June 30, 2016 and are reported within the Selling, general and administrative expenses line in the Condensed Consolidated Statements of Loss. The useful lives on FSC acquired intangible assets range from seven to ten years.

After its acquisition on February 5, 2016, FSC contributed $1,761 and $2,637 to the Company's net sales for the three and six month periods ended June 30, 2016, respectively. Concurrently, the net impact of the FSC acquisition was a loss of $3,096 and $4,489 for the three and six month periods ended June 30, 2016, respectively.

Had the FSC acquisition been completed as of the beginning of 2015, the Company's unaudited pro forma net sales and net loss for the six months ended June 30, 2016 and 2015 would have been as follows:

	Six Months Ended
Pro Forma Net Revenue and Losses	June 30, 2016		June 30, 2015
Net revenues	$	75,549	$	83,579
Net loss		(27,030)		(9,395)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 6 : Goodwill and Intangible Assets

The Company's amortizable and unamortizable intangible assets at June 30, 2016 and December 31, 2015 are as follows:

	June 30, 2016						December 31, 2015
	Gross Value		Accumulated Amortization		Net Carrying Amount		Gross Value		Accumulated Amortization		Net Carrying Amount
Amortizable intangible assets:
Acquired developed technology - Bloxiverz	$	35,248	$	(29,373)	$	5,875	$	35,248	$	(23,498)	$	11,750
Acquired developed technology - Vazculep		12,061		(8,394)		3,667		12,061		(7,986)		4,075
Acquired developed technology - Flexichamber		4,400		(183)		4,217		-		-		-
Acquired product marketing rights		16,200		(750)		15,450		-		-		-
Total amortizable intangible assets	$	67,909	$	(38,700)	$	29,209	$	47,309	$	(31,484)	$	15,825

Unamortizable intangible assets:
Goodwill	$	18,669	$	-	$	18,669	$	18,491	$	-	$	18,491
Total unamortizable intangible assets	$	18,669	$	-	$	18,669	$	18,491	$	-	$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $3,702 and $3,139 for the three months ended June 30, 2016 and 2015, respectively. The Company recorded amortization expense related to amortizable intangible assets of $7,216 and $6,282 for the six months ended June 30, 2016 and 2015, respectively. Accumulated amortization in the above tables includes an impairment charge of $7,171 which was recognized during the year ended December 31, 2012 relative to the “Acquired developed technology – Vazculep” intangible asset.

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to ten years. Estimated amortization of intangible assets for the next five years is as follows:

Years ending December 31,	Estimated Amortization Expense
2016	$	14,616
2017		3,056
2018		3,056
2019		3,056
2020		3,056
Total	$	26,840

The change in net goodwill during the six months ended June 30, 2016 is as follows:

Goodwill:
Balance - December 31, 2015	$	18,491
Impact of FSC acquisition		178
Balance, June 30 2016	$	18,669

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Related Party Payable

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

NOTE 7 : Long-Term Related Party Payable

Long-term related party payable and related activity are reported at fair value and consist of the following at June 30, 2016 and December 31, 2015:

			Activity during Six-Months Ended June 30, 2016

							Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015		Additions		Payments to Related Parties		Operating Expense		Other Expense		Balance, June 30, 2016

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	20,617	$	-	$	-	$	(5,155)	$	-	$	15,462
Earn-out payments - Éclat Pharmaceuticals (b)		90,468		-		(14,216)		38,362		-		114,614
Royalty agreement - FSC (c)		-		7,695		(124)		(1,066)		-		6,505
Financing-related:
Royalty agreement - Deerfield (d)		7,862		-		(1,337)		-		2,915		9,440
Royalty agreement - Broadfin (e)		3,746		-		(638)		-		1,392		4,500
Long-term liability - FSC (f)		-		15,000		-		-		-		15,000
Total related party payable		122,693	$	22,695	$	(16,315)	$	32,141	$	4,307		165,521
Less: Current portion		(25,204)										(29,500)
Total long-term related party payable	$	97,489									$	136,021

(a)

As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of June 30:

Deerfield Warrant Valuation	June 30, 2016			June 30, 2015

Weighted average exercise price per share		$ 8.63		$	8.63
Expected term (years)		1.75			2.75
Expected volatility		69.70	%		62.90	%
Risk-free interest rate		0.55	%		0.92	%
Expected dividend yield		-			-

These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date.

Expected term: The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life.

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price for a period approximating the expected term.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The Company has not distributed any dividends since its inception, and has no plan to distribute dividends in the foreseeable future.

At the closing date of the 2012 Éclat acquisition and at June 30, 2016, it was uncertain as to whether the Company would ultimately fulfill its obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a long-term liability. This classification as a long-term liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro.

(b)

In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.

(c)

In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

(d)

As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.

(e)

As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.

(f)

In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000.

At June 30, 2016, the fair value of each related party payable listed in (b) through (e) above was estimated using a discounted cash flow model based on probability-adjusted annual net revenues or gross profit, as appropriate, of each of the specified Éclat and FSC products using an appropriate risk-adjusted discount rate ranging from 15% to 32%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related contingent consideration payable, resulting primarily from management’s revision of key assumptions, will be recorded in the ‘Changes in fair value of related party contingent consideration’ line within the Company’s Condensed Consolidated Statements of Loss.

The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (d) and (e) above. These financing-related liabilities are recorded at fair market value on the Condensed Consolidated Balance Sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the Condensed Consolidated Statements of Loss.

Income Taxes

6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 8 : Income Taxes

The components of income (loss) before income taxes are as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015

United States	$	(2,187)	$	4,050	$	11,762	$	20,773
France		(2,288)		(1,123)		(9,089)		9,113
Ireland		(8,034)		(11,278)		(13,928)		(16,317)
Total income (loss) before income taxes	$	(12,509)	$	(8,351)	$	(11,255)	$	13,569

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015

Statutory tax rate		33.3	%		33.3	%		33.3	%		33.3	%
International tax rates differential		(13.2)	%		(31.8)	%		(27.7)	%		27.6	%
Valuation allowance on net operating losses		(11.9)	%		(16.0)	%		(34.8)	%		2.4	%
Nondeductible contingent consideration		(64.2)	%		(132.3)	%		(96.0)	%		90.9	%
Nondeductible stock-based compensation		(1.7)	%		38.9	%		(3.9)	%		(26.4)	%
Deferred charge from IP transfer		-			(0.2)	%		(4.4)	%		0.5	%
State and local income taxes		(2.8)	%		(1.6)	%		(4.2)	%		1.9	%
Other		0.9	%		8.0	%		6.4	%		(3.4)	%
Effective income tax rate		(59.5)	%		(101.9)	%		(131.2)	%		126.9	%

Income tax provision - at Statutory tax rate	$	(4,165)		$	(2,781)		$	(3,748)		$	4,518
International tax rates differential		1,647			2,658			3,115			3,748
Valuation allowance on net operating losses		1,485			1,338			3,913			332
Nondeductible contingent consideration		8,029			11,049			10,800			12,329
Nondeductible stock-based compensation		216			(3,246)			434			(3,579)
Deferred charge from IP transfer		(1)			17			493			69
State and local income taxes		356			136			477			255
Other		(118)			(664)			(723)			(458)
Income tax provision - at Effective income tax rate	$	7,449		$	8,507		$	14,761		$	17,214

The income tax provision for the three months ended June 30, 2016 and 2015 was $7,449 and $8,507, respectively. The decrease in the income tax provision for the three months ended June 30, 2016 is primarily the result of decreases in the amount of pre-tax income recorded in the United States and France, when compared to the same period in 2015. The decrease in the income tax provision for the three months ended June 30, 2016 would have been larger, but a tax benefit from stock-based compensation recorded in the same period in 2015 did not repeat in 2016.

The income tax provision for the six months ended June 30, 2016 and 2015 was $14,761 and $17,214, respectively. The decrease in the income tax provision for the six months ended June 30, 2016 is primarily the result of decreases in the amount of pre-tax income recorded in the United States and France, when compared to the same period in 2015. The decrease in the income tax provision for the six months ended June 30, 2016 would have been larger, but a tax benefit from stock-based compensation recorded in the same period in 2015 did not repeat in 2016 and the Company was required to record a valuation allowance against the net operating losses generated in France in 2016.

Other Assets and Liabilities

6 Months Ended

Jun. 30, 2016

Other Liabilities Disclosure [Abstract]

Other Liabilities Disclosure [Text Block]

NOTE 9 : Other Assets and Liabilities

Various other assets and liabilities are summarized as follows:

	June 30,		December 31,
Prepaid expenses and other current assets:	2016		2015

Valued-added tax recoverable	$	1,216	$	1,099
Prepaid expenses		3,457		2,921
Advance to suppliers and other current assets		1,604		518
Income tax receivable		3,380		3,526
Total	$	9,657	$	8,064

	June 30,		December 31,
Other non-current assets:	2016		2015

Deferred tax assets	$	5,542	$	-
Other		119		167
Total	$	5,661	$	167

	June 30,		December 31,
Accrued expenses:	2016		2015

Accrued compensation	$	2,383	$	1,888
Accrued social charges		1,132		1,710
Accrued trade discounts and rebates		6,914		5,710
Other		163		-
Total	$	10,592	$	9,308

	June 30,		December 31,
Other current liabilities:	2016		2015

Valued-added tax payable	$	185	$	-
Other		479		133
Total	$	664	$	133

	June 30,		December 31,
Other non-current liabilities:	2016		2015

Provision for retirement indemnity	$	2,274	$	2,170
Other		597		356
Total	$	2,871	$	2,526

Net Loss Per Share

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 10 : Net Loss Per Share

Basic net loss per share is calculated using the weighted average number of shares outstanding during each period. The diluted net loss per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants.

A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Loss Per Share	2016		2015		2016		2015

Net loss	$	(19,958)	$	(16,858)	$	(26,016)	$	(3,645)

Weighted average shares:
Basic shares		41,241		40,353		41,241		40,281
Effect of dilutive securities—options and warrants outstanding		-		-		-		-
Diluted shares		41,241		40,353		41,241		40,281

Net loss per share - basic	$	(0.48)	$	(0.42)	$	(0.63)	$	(0.09)
Net loss per share - diluted	$	(0.48)	$	(0.42)	$	(0.63)	$	(0.09)

Potential common shares of 6,596 and 6,634 were excluded from the calculation of weighted average shares for the three and six months ended June 30, 2016 and 2015, respectively, because their effect was considered to be anti-dilutive.

Comprehensive Income (Loss)

6 Months Ended

Jun. 30, 2016

Stockholders' Equity Note [Abstract]

Comprehensive Income (Loss) Note [Text Block]

NOTE 11 : Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive loss for the three and six months ended June 30, 2016 and 2015, net of tax effects:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Accumulated Other Comprehensive Loss	2016		2015		2016		2015

Foreign currency translation adjustment:
Beginning balance	$	(17,495)	$	(23,874)	$	(22,312)	$	(7,225)
Net other comprehensive (loss) income		(2,457)		5,262		2,360		(11,387)
Balance at June 30	$	(19,952)	$	(18,612)	$	(19,952)	$	(18,612)

Unrealized gain (loss) on marketable securities, net
Beginning balance	$	574	$	158	$	(345)	$	(198)
Net other comprehensive (loss) income, net of ($73), $0, ($158), $0 tax		528		(356)		1,447		-
Balance at June 30	$	1,102	$	(198)	$	1,102	$	(198)

Accumulated Other Comprehensive Loss at June 30	$	(18,850)	$	(18,810)	$	(18,850)	$	(18,810)

The effect on the Company’s condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Shareholders' Equity

6 Months Ended

Jun. 30, 2016

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

NOTE 12 : Shareholders’ Equity

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the six months ended June 30, 2016:

	Six Months Ended
Shareholders' Equity	June 30, 2016

Shareholders' equity - January 1	$	69,134
Net loss		(26,016)
Other comprehensive income		3,807
Stock-based compensation expense		4,913
Shareholders' equity - June 30	$	51,838

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Company Operations by Product

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

NOTE 13 : Company Operations by Product

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Revenues	2016		2015		2016		2015

Bloxiverz	$	25,620	$	44,283	$	50,367	$	72,726
Vazculep		10,421		3,627		19,827		7,151
Other		2,124		692		3,324		1,251
Total product sales and services		38,165		48,602		73,518		81,128
License and research revenue		693		-		1,556		-
Total revenues	$	38,858	$	48,602	$	75,074	$	81,128

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

NOTE 14 : Commitments and Contingencies

Litigation

The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At June 30, 2016 and December 31, 2015, there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s condensed consolidated financial position, results of operations, cash flows or liquidity.

Material Commitments

Other than commitments to Recipharm and for operating leases as disclosed in Note 12 - Contingent Liabilities and Commitments to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt, and post-retirement benefit plan obligations which are disclosed in Note 7 - Long-Term Debt and Note 10 – Post-Retirement Benefit Plans, respectively, to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report and long-term contingent consideration payable as disclosed in Note 7 – Long-term Related Party Payable, to the Company's condensed consolidated financial statements included in Part I, Item 1 of this report.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Nature Of Business Policy [Policy Text Block]

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri, United States, and Dublin, Ireland.

Basis of Accounting, Policy [Policy Text Block]

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Reclassification, Policy [Policy Text Block]

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:

	Three Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			As revised

Product sales and services	$	49,795		$	-		$	-		$	(1,193	)	$	48,602
Total revenue		49,795			-			-			(1,193	)		48,602
Operating income (loss)		(1,177	)		-			-			(1,193	)		(2,370	)
Income (loss) before income taxes		(7,158	)		-			-			(1,193	)		(8,351	)
Income tax provision		10,242			(292	)		(1,026	)		(417	)		8,507
Net loss		(17,400	)		292			1,026			(776	)		(16,858	)
Net loss per share - basic	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)
Net loss per share - diluted	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)

	Six Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	82,521		$	-		$	-		$	(1,193	)	$	(200	)	$	81,128
Total revenue		82,521			-			-			(1,193	)		(200	)		81,128
Operating income (loss)		9,037			-			-			(1,193	)		(200	)		7,644
Income (loss) before income taxes		14,962			-			-			(1,193	)		(200	)		13,569
Income tax provision		20,715			(1,158	)		(1,856	)		(417	)		(70	)		17,214
Net loss		(5,753	)		1,158			1,856			(776	)		(130	)		(3,645	)
Net loss per share - basic	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)
Net loss per share - diluted	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)

	December 31, 2015
				*Correction of Immaterial Errors*									*Reclassifications*
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	-		$	-		$	-		$	509		$	-	$	7,487
Inventories		4,155			-			(489	)		-			-			-		3,666
Prepaid expenses and other current assets		7,989			-			-			-			-			75		8,064
Total current assets		166,306			-			(489	)		-			509			75		166,401
Other		158			-			-			-			-			9		167
Total assets		214,977			-			(489	)		-			509			84		215,081
Current portion of long-term related party payable		28,614			-			-			(3,410	)		-			-		25,204
Accounts payable		10,565			-			-			-			(5,517	)		-		5,048
Accrued expenses		3,598			-			-			-			5,710			-		9,308
Income taxes		323			(227	)		(171	)		-			-			75		-
Total current liabilities		48,788			(227	)		(171	)		(3,410	)		193			75		45,248
Long-term related party payable, less current portion		94,079			-			-			3,410			-			-		97,489
Deferred taxes		1,351			(1,360	)		-			-			-			9		-
Other		2,210			-			-			-			316			-		2,526
Total liabilities		147,112			(1,587	)		(171	)		-			509			84		145,947
Accumulated deficit		(279,793	)		1,587			(318	)		-			-			-		(278,524	)
Total shareholders' equity		67,865			1,587			(318	)		-			-			-		69,134
Total liabilities and shareholders' equity		214,977			-			(489	)		-			509			84		215,081

(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)	Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(c)	Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014.

(d)	Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.

(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.

(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

Revenue Recognition, Policy [Policy Text Block]

Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, milestone payments for R&D achievements, and compensation for the execution of R&D activities.

Product Sales and Services

License and Research Revenue

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:

	Three Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			As revised

Product sales and services	$	49,795		$	-		$	-		$	(1,193	)	$	48,602
Total revenue		49,795			-			-			(1,193	)		48,602
Operating income (loss)		(1,177	)		-			-			(1,193	)		(2,370	)
Income (loss) before income taxes		(7,158	)		-			-			(1,193	)		(8,351	)
Income tax provision		10,242			(292	)		(1,026	)		(417	)		8,507
Net loss		(17,400	)		292			1,026			(776	)		(16,858	)
Net loss per share - basic	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)
Net loss per share - diluted	$	(0.43	)	$	0.01		$	0.02		$	(0.02	)	$	(0.42	)

	Six Months Ended
	June 30, 2015
				*Correction of Immaterial Errors*
Consolidated Statement of Loss:	As filed			(a)			(b)			(c)			(d)			As revised

Product sales and services	$	82,521		$	-		$	-		$	(1,193	)	$	(200	)	$	81,128
Total revenue		82,521			-			-			(1,193	)		(200	)		81,128
Operating income (loss)		9,037			-			-			(1,193	)		(200	)		7,644
Income (loss) before income taxes		14,962			-			-			(1,193	)		(200	)		13,569
Income tax provision		20,715			(1,158	)		(1,856	)		(417	)		(70	)		17,214
Net loss		(5,753	)		1,158			1,856			(776	)		(130	)		(3,645	)
Net loss per share - basic	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)
Net loss per share - diluted	$	(0.14	)	$	0.03		$	0.04		$	(0.02	)	$	-		$	(0.09	)

	December 31, 2015
				*Correction of Immaterial Errors*									*Reclassifications*
Consolidated Balance Sheet:	As filed			(a)			(e)			(f)			(g)			(h)		As revised

Accounts receivable	$	6,978		$	-		$	-		$	-		$	509		$	-	$	7,487
Inventories		4,155			-			(489	)		-			-			-		3,666
Prepaid expenses and other current assets		7,989			-			-			-			-			75		8,064
Total current assets		166,306			-			(489	)		-			509			75		166,401
Other		158			-			-			-			-			9		167
Total assets		214,977			-			(489	)		-			509			84		215,081
Current portion of long-term related party payable		28,614			-			-			(3,410	)		-			-		25,204
Accounts payable		10,565			-			-			-			(5,517	)		-		5,048
Accrued expenses		3,598			-			-			-			5,710			-		9,308
Income taxes		323			(227	)		(171	)		-			-			75		-
Total current liabilities		48,788			(227	)		(171	)		(3,410	)		193			75		45,248
Long-term related party payable, less current portion		94,079			-			-			3,410			-			-		97,489
Deferred taxes		1,351			(1,360	)		-			-			-			9		-
Other		2,210			-			-			-			316			-		2,526
Total liabilities		147,112			(1,587	)		(171	)		-			509			84		145,947
Accumulated deficit		(279,793	)		1,587			(318	)		-			-			-		(278,524	)
Total shareholders' equity		67,865			1,587			(318	)		-			-			-		69,134
Total liabilities and shareholders' equity		214,977			-			(489	)		-			509			84		215,081

(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)	Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(c)	Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014.

(d)	Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

(e)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.

(f)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.

(g)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(h)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:

	June 30,		December 31,
Marketable Securities:	2016		2015

Value at cost	$	131,041	$	81,395
Gross unrealized holding gains		1,236		15
Gross unrealized holding losses		(1,313)		(1,672)
Fair value	$	130,964	$	79,738

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

The principal categories of inventories at June 30, 2016 and December 31, 2015 are as follows:

	June 30,		December 31,
Inventory:	2016		2015

Finished Goods	$	3,280	$	2,545
Raw Materials		360		1,121
Total	$	3,640	$	3,666

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2016

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Assigned Fair Value:	2016 Preliminary

Accounts receivable	$	825
Inventories		2,315
Prepaid expenses and other current assets		1,712
Goodwill		178
Intangible assets:
Acquired product marketing rights		16,200
Acquired developed technology		4,400
Other assets		392
Accounts payable and other current liabilities		(3,794)
Total	$	22,228

Business Acquisition, Pro Forma Information [Table Text Block]

	Six Months Ended
Pro Forma Net Revenue and Losses	June 30, 2016		June 30, 2015
Net revenues	$	75,549	$	83,579
Net loss		(27,030)		(9,395)

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The Company's amortizable and unamortizable intangible assets at June 30, 2016 and December 31, 2015 are as follows:

	June 30, 2016						December 31, 2015
	Gross Value		Accumulated Amortization		Net Carrying Amount		Gross Value		Accumulated Amortization		Net Carrying Amount
Amortizable intangible assets:
Acquired developed technology - Bloxiverz	$	35,248	$	(29,373)	$	5,875	$	35,248	$	(23,498)	$	11,750
Acquired developed technology - Vazculep		12,061		(8,394)		3,667		12,061		(7,986)		4,075
Acquired developed technology - Flexichamber		4,400		(183)		4,217		-		-		-
Acquired product marketing rights		16,200		(750)		15,450		-		-		-
Total amortizable intangible assets	$	67,909	$	(38,700)	$	29,209	$	47,309	$	(31,484)	$	15,825

Unamortizable intangible assets:
Goodwill	$	18,669	$	-	$	18,669	$	18,491	$	-	$	18,491
Total unamortizable intangible assets	$	18,669	$	-	$	18,669	$	18,491	$	-	$	18,491

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to ten years. Estimated amortization of intangible assets for the next five years is as follows:

Years ending December 31,	Estimated Amortization Expense
2016	$	14,616
2017		3,056
2018		3,056
2019		3,056
2020		3,056
Total	$	26,840

Schedule of Goodwill [Table Text Block]

The change in net goodwill during the six months ended June 30, 2016 is as follows:

Goodwill:
Balance - December 31, 2015	$	18,491
Impact of FSC acquisition		178
Balance, June 30 2016	$	18,669

Long-Term Related Party Payable (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Long-term related party payable and related activity are reported at fair value and consist of the following at June 30, 2016 and December 31, 2015:

			Activity during Six-Months Ended June 30, 2016

							Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015		Additions		Payments to Related Parties		Operating Expense		Other Expense		Balance, June 30, 2016

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	20,617	$	-	$	-	$	(5,155)	$	-	$	15,462
Earn-out payments - Éclat Pharmaceuticals (b)		90,468		-		(14,216)		38,362		-		114,614
Royalty agreement - FSC (c)		-		7,695		(124)		(1,066)		-		6,505
Financing-related:
Royalty agreement - Deerfield (d)		7,862		-		(1,337)		-		2,915		9,440
Royalty agreement - Broadfin (e)		3,746		-		(638)		-		1,392		4,500
Long-term liability - FSC (f)		-		15,000		-		-		-		15,000
Total related party payable		122,693	$	22,695	$	(16,315)	$	32,141	$	4,307		165,521
Less: Current portion		(25,204)										(29,500)
Total long-term related party payable	$	97,489									$	136,021

(a)

(b)

(c)

(d)

(e)

(f)

Schedule Of Fair Value Assumptions Of Warrant [Table Text Block]

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of June 30:

Deerfield Warrant Valuation	June 30, 2016			June 30, 2015

Weighted average exercise price per share		$ 8.63		$	8.63
Expected term (years)		1.75			2.75
Expected volatility		69.70	%		62.90	%
Risk-free interest rate		0.55	%		0.92	%
Expected dividend yield		-			-

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Before Income Tax [Table Text Block]

The components of income (loss) before income taxes are as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015

United States	$	(2,187)	$	4,050	$	11,762	$	20,773
France		(2,288)		(1,123)		(9,089)		9,113
Ireland		(8,034)		(11,278)		(13,928)		(16,317)
Total income (loss) before income taxes	$	(12,509)	$	(8,351)	$	(11,255)	$	13,569

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Statutory tax rate		33.3	%		33.3	%		33.3	%		33.3	%
International tax rates differential		(13.2)	%		(31.8)	%		(27.7)	%		27.6	%
Valuation allowance on net operating losses		(11.9)	%		(16.0)	%		(34.8)	%		2.4	%
Nondeductible contingent consideration		(64.2)	%		(132.3)	%		(96.0)	%		90.9	%
Nondeductible stock-based compensation		(1.7)	%		38.9	%		(3.9)	%		(26.4)	%
Deferred charge from IP transfer		-			(0.2)	%		(4.4)	%		0.5	%
State and local income taxes		(2.8)	%		(1.6)	%		(4.2)	%		1.9	%
Other		0.9	%		8.0	%		6.4	%		(3.4)	%
Effective income tax rate		(59.5)	%		(101.9)	%		(131.2)	%		126.9	%

Income tax provision - at Statutory tax rate	$	(4,165)		$	(2,781)		$	(3,748)		$	4,518
International tax rates differential		1,647			2,658			3,115			3,748
Valuation allowance on net operating losses		1,485			1,338			3,913			332
Nondeductible contingent consideration		8,029			11,049			10,800			12,329
Nondeductible stock-based compensation		216			(3,246)			434			(3,579)
Deferred charge from IP transfer		(1)			17			493			69
State and local income taxes		356			136			477			255
Other		(118)			(664)			(723)			(458)
Income tax provision - at Effective income tax rate	$	7,449		$	8,507		$	14,761		$	17,214

Other Assets and Liabilities (Tables)

6 Months Ended

Jun. 30, 2016

Other Liabilities Disclosure [Abstract]

Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]

Various other assets and liabilities are summarized as follows:

	June 30,		December 31,
Prepaid expenses and other current assets:	2016		2015

Valued-added tax recoverable	$	1,216	$	1,099
Prepaid expenses		3,457		2,921
Advance to suppliers and other current assets		1,604		518
Income tax receivable		3,380		3,526
Total	$	9,657	$	8,064

Schedule of Other Assets, Noncurrent [Table Text Block]

	June 30,		December 31,
Other non-current assets:	2016		2015

Deferred tax assets	$	5,542	$	-
Other		119		167
Total	$	5,661	$	167

Schedule of Accrued Liabilities [Table Text Block]

	June 30,		December 31,
Accrued expenses:	2016		2015

Accrued compensation	$	2,383	$	1,888
Accrued social charges		1,132		1,710
Accrued trade discounts and rebates		6,914		5,710
Other		163		-
Total	$	10,592	$	9,308

Schedule Of Other Current Liabilities [Table Text Block]

	June 30,		December 31,
Other current liabilities:	2016		2015

Valued-added tax payable	$	185	$	-
Other		479		133
Total	$	664	$	133

Schedule Of Long Term Liabilities [Table Text Block]

	June 30,		December 31,
Other non-current liabilities:	2016		2015

Provision for retirement indemnity	$	2,274	$	2,170
Other		597		356
Total	$	2,871	$	2,526

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation [Table Text Block]

A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Loss Per Share	2016		2015		2016		2015

Net loss	$	(19,958)	$	(16,858)	$	(26,016)	$	(3,645)

Weighted average shares:
Basic shares		41,241		40,353		41,241		40,281
Effect of dilutive securities—options and warrants outstanding		-		-		-		-
Diluted shares		41,241		40,353		41,241		40,281

Net loss per share - basic	$	(0.48)	$	(0.42)	$	(0.63)	$	(0.09)
Net loss per share - diluted	$	(0.48)	$	(0.42)	$	(0.63)	$	(0.09)

Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 30, 2016

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The following table shows the components of accumulated other comprehensive loss for the three and six months ended June 30, 2016 and 2015, net of tax effects:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Accumulated Other Comprehensive Loss	2016		2015		2016		2015

Foreign currency translation adjustment:
Beginning balance	$	(17,495)	$	(23,874)	$	(22,312)	$	(7,225)
Net other comprehensive (loss) income		(2,457)		5,262		2,360		(11,387)
Balance at June 30	$	(19,952)	$	(18,612)	$	(19,952)	$	(18,612)

Unrealized gain (loss) on marketable securities, net
Beginning balance	$	574	$	158	$	(345)	$	(198)
Net other comprehensive (loss) income, net of ($73), $0, ($158), $0 tax		528		(356)		1,447		-
Balance at June 30	$	1,102	$	(198)	$	1,102	$	(198)

Accumulated Other Comprehensive Loss at June 30	$	(18,850)	$	(18,810)	$	(18,850)	$	(18,810)

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2016

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity [Table Text Block]

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the six months ended June 30, 2016:

	Six Months Ended
Shareholders' Equity	June 30, 2016

Shareholders' equity - January 1	$	69,134
Net loss		(26,016)
Other comprehensive income		3,807
Stock-based compensation expense		4,913
Shareholders' equity - June 30	$	51,838

Company Operations by Product (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following table presents a summary of total revenues by these products:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Revenues	2016		2015		2016		2015

Bloxiverz	$	25,620	$	44,283	$	50,367	$	72,726
Vazculep		10,421		3,627		19,827		7,151
Other		2,124		692		3,324		1,251
Total product sales and services		38,165		48,602		73,518		81,128
License and research revenue		693		-		1,556		-
Total revenues	$	38,858	$	48,602	$	75,074	$	81,128

Summary of Significant Accounting Policies (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

$ 38,165

$ 48,602

$ 73,518

$ 81,128

Total revenue

38,858

48,602

75,074

81,128

Operating income (loss)

(11,543)

(2,370)

(5,839)

7,644

Income (loss) before income taxes

(12,509)

(8,351)

(11,255)

13,569

Income tax provision

7,449

8,507

14,761

17,214

Net loss

$ (19,958)

$ (16,858)

$ (26,016)

$ (3,645)

Net loss per share - basic

$ (0.48)

$ (0.42)

$ (0.63)

$ (0.09)

Net loss per share - diluted

$ (0.48)

$ (0.42)

$ (0.63)

$ (0.09)

Restatement Adjustment [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Income tax provision

$ 1,193

Scenario, Previously Reported [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

49,795

$ 82,521

Total revenue

49,795

82,521

Operating income (loss)

(1,177)

9,037

Income (loss) before income taxes

(7,158)

14,962

Income tax provision

10,242

20,715

Net loss

$ (17,400)

$ (5,753)

Net loss per share - basic

$ (0.43)

$ (0.14)

Net loss per share - diluted

$ (0.43)

$ (0.14)

Adjustment A [Member] | Restatement Adjustment [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

^[1]

$ 0

Total revenue

^[1]

Operating income (loss)

^[1]

Income (loss) before income taxes

^[1]

Income tax provision

$ (434)

$ 863

(292)

^[1]

$ 866

(1,158)

^[1]

$ 1,587

Net loss

^[1]

$ 292

$ 1,158

Net loss per share - basic

^[1]

$ 0.01

$ 0.03

Net loss per share - diluted

^[1]

$ 0.01

$ 0.03

Adjustment B [Member] | Restatement Adjustment [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

^[2]

$ 0

Total revenue

^[2]

Operating income (loss)

^[2]

Income (loss) before income taxes

^[2]

Income tax provision

$ 2,606

$ 750

(1,026)

^[2]

830

(1,856)

^[2]

$ (693)

$ 333

$ 360

Net loss

^[2]

$ 1,026

$ 1,856

Net loss per share - basic

^[2]

$ 0.02

$ 0.04

Net loss per share - diluted

^[2]

$ 0.02

$ 0.04

Adjustment C [Member] | Restatement Adjustment [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

^[3]

$ (1,193)

Total revenue

^[3]

(1,193)

Operating income (loss)

^[3]

(1,193)

Income (loss) before income taxes

^[3]

(1,193)

Income tax provision

^[3]

(417)

Net loss

^[3]

$ (776)

Net loss per share - basic

^[3]

$ (0.02)

Net loss per share - diluted

^[3]

$ (0.02)

Adjustment D [Member] | Restatement Adjustment [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Product sales and services

^[4]

$ (200)

Total revenue

$ 200

(200)

^[4]

Operating income (loss)

^[4]

(200)

Income (loss) before income taxes

^[4]

(200)

Income tax provision

^[4]

(70)

Net loss

^[4]

$ (130)

Net loss per share - basic

^[4]

$ 0

Net loss per share - diluted

^[4]

$ 0

[1]	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).
[2]	Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.
[3]	Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014.
[4]	Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.

Summary of Significant Accounting Policies (Details 1) - USD ($)
$ in Thousands

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

$ 9,488

$ 7,487

Inventories

3,640

3,666

Prepaid expenses and other current assets

9,657

8,064

Total current assets

177,648

166,401

Other

5,661

167

Total assets

249,706

215,081

Current portion of long-term related party payable

29,500

25,204

Accounts payable

7,043

5,048

Accrued expenses

10,592

9,308

Income taxes

6,286

Total current liabilities

58,188

45,248

136,021

97,489

Deferred taxes

Other

2,871

2,526

Total liabilities

197,868

145,947

Accumulated deficit

(304,540)

(278,524)

Total shareholders' equity

51,838

69,134

Total liabilities and shareholders' equity

$ 249,706

215,081

Reclassification Adjustment G [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

^[1]

509

Inventories

^[1]

Prepaid expenses and other current assets

^[1]

Total current assets

^[1]

509

Other

^[1]

Total assets

^[1]

509

Current portion of long-term related party payable

^[1]

Accounts payable

^[1]

(5,517)

Accrued expenses

^[1]

5,710

Income taxes

^[1]

Total current liabilities

^[1]

193

^[1]

Deferred taxes

^[1]

Other

^[1]

316

Total liabilities

^[1]

509

Accumulated deficit

^[1]

Total shareholders' equity

^[1]

Total liabilities and shareholders' equity

^[1]

509

Reclassification Adjustment H [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

^[2]

Inventories

^[2]

Prepaid expenses and other current assets

^[2]

Total current assets

^[2]

Other

^[2]

Total assets

^[2]

Current portion of long-term related party payable

^[2]

Accounts payable

^[2]

Accrued expenses

^[2]

Income taxes

^[2]

Total current liabilities

^[2]

^[2]

^[2]

^[2]

^[2]

Total shareholders' equity

^[2]

Total liabilities and shareholders' equity

^[2]

Scenario, Previously Reported [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

6,978

Inventories

4,155

Prepaid expenses and other current assets

7,989

Total current assets

166,306

Other

158

Total assets

214,977

Current portion of long-term related party payable

28,614

Accounts payable

10,565

Accrued expenses

3,598

Income taxes

323

Total current liabilities

48,788

94,079

1,351

2,210

147,112

(279,793)

Total shareholders' equity

67,865

Total liabilities and shareholders' equity

214,977

Restatement Adjustment [Member] | Adjustment A [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

^[3]

Inventories

^[3]

Prepaid expenses and other current assets

^[3]

Total current assets

^[3]

Other

^[3]

Total assets

^[3]

Current portion of long-term related party payable

^[3]

Accounts payable

^[3]

Accrued expenses

^[3]

Income taxes

^[3]

(227)

Total current liabilities

^[3]

(227)

^[3]

Deferred taxes

^[3]

(1,360)

Other

^[3]

Total liabilities

^[3]

(1,587)

Accumulated deficit

^[3]

1,587

Total shareholders' equity

^[3]

1,587

Total liabilities and shareholders' equity

^[3]

Restatement Adjustment [Member] | Adjustment E [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

^[4]

Inventories

$ 489

(489)

^[4]

Prepaid expenses and other current assets

^[4]

Total current assets

^[4]

(489)

Other

^[4]

Total assets

^[4]

(489)

Current portion of long-term related party payable

^[4]

Accounts payable

^[4]

Accrued expenses

^[4]

Income taxes

^[4]

(171)

Total current liabilities

^[4]

(171)

^[4]

Deferred taxes

^[4]

Other

^[4]

Total liabilities

^[4]

(171)

Accumulated deficit

^[4]

(318)

Total shareholders' equity

^[4]

(318)

Total liabilities and shareholders' equity

^[4]

(489)

Restatement Adjustment [Member] | Adjustment F [Member]

Error Corrections and Prior Period Adjustments Restatement [Line Items]

Accounts receivable

^[5]

Inventories

^[5]

Prepaid expenses and other current assets

^[5]

Total current assets

^[5]

Other

^[5]

Total assets

^[5]

Current portion of long-term related party payable

^[5]

(3,410)

Accounts payable

^[5]

Accrued expenses

^[5]

Income taxes

^[5]

Total current liabilities

^[5]

(3,410)

^[5]

3,410

^[5]

^[5]

^[5]

^[5]

Total shareholders' equity

^[5]

Total liabilities and shareholders' equity

^[5]

$ 0

[1]	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.
[2]	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (g) above.
[3]	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).
[4]	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.
[5]	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.

Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2016

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Income Tax Expense (Benefit)

$ 7,449

$ 8,507

$ 14,761

$ 17,214

Revenue from Change in Accounting Estimate

5,981

Revenues

38,858

48,602

75,074

81,128

Inventory, Net

3,640

$ 3,666

3,640

$ 3,666

Due to Related Parties, Current

$ 29,500

25,204

$ 29,500

25,204

Additional Diluted Net Earnings (Loss) Per Share

$ 0.05

Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Income Tax Expense (Benefit)

1,193

Adjustment A [Member] | Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Income Tax Expense (Benefit)

(434)

$ 863

(292)

^[1]

$ 866

(1,158)

^[1]

1,587

Revenues

^[1]

Inventory, Net

^[1]

Due to Related Parties, Current

^[1]

Adjustment B [Member] | Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Income Tax Expense (Benefit)

2,606

$ 750

(1,026)

^[2]

830

(1,856)

^[2]

$ (693)

$ 333

$ 360

Revenues

^[2]

$ 0

Adjustment D [Member] | Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Income Tax Expense (Benefit)

^[3]

(70)

Revenues

$ 200

$ (200)

^[3]

Adjustment E [Member] | Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Inventory, Net

(489)

^[4]

(489)

^[4]

$ 489

Due to Related Parties, Current

^[4]

Adjustment F [Member] | Restatement Adjustment [Member]

Nature Of Business And Summary Of Significant Accounting Policies [Line Items]

Inventory, Net

^[5]

Due to Related Parties, Current

^[5]

$ (3,410)

[1]	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).
[2]	Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.
[3]	Reflects the correction of a $1,193 understatement in the second quarter of 2015 of the gross to net revenue reserves with respect to estimates for product returns as a result of improper reconciliation to revenue data communicated by service providers. As this item was originally corrected in the third quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.
[4]	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.
[5]	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.

Marketable Securities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Marketable Securities [Line Items]
Value at cost	$ 131,913	$ 81,395
Gross unrealized holding gains	1,851	15
Gross unrealized holding losses	(2,800)	(1,672)
Fair value	$ 130,964	$ 79,738

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Finished Goods	$ 3,280	$ 2,545
Raw Materials	360	1,121
Total	$ 3,640	$ 3,666

Acquisitions (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Inventories	$ 2,315
Prepaid expenses and other current assets	1,712
Goodwill	18,669	$ 18,491
Intangible assets:
Other assets	392
Accounts receivable	825
Accounts payable and other current liabilities	(3,794)
Net identifiable assets acquired	22,228
Product marketing rights [Member]
Intangible assets:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	16,200
Developed Technology Rights [Member]
Intangible assets:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 4,400

Acquisitions (Details 1) - USD ($) $ in Thousands	6 Months Ended
Acquisitions (Details 1) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Net revenues	$ 75,549	$ 83,579
Net loss	$ (27,030)	$ (9,395)

Acquisitions (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
Acquisitions (Details Textual) - USD ($) $ in Thousands	Feb. 05, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2016
Business Combination, Separately Recognized Transactions [Line Items]
Payments to Acquire Businesses, Gross				$ 16,315
Business Combination Royalty Payable Description	the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ 3,096	4,489
Deerfield CSF LLC [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	$ 15,000
Payments to Acquire Businesses, Gross	1,050
Business Combination, Contingent Consideration, Liability, Total	7,695
FSC Holdings, LLC [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Consideration Transferred, Total	22,228
Payments to Acquire Businesses, Gross		$ 1,050
Business Combination Royalty Payable Description		commitments to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			1,761	2,637
Business Acquisition, Transaction Costs			$ 76	$ 76
Payment For Settlement Of Net Working Capital	$ 467
FSC Holdings, LLC [Member] \| Maximum [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Finite-Lived Intangible Asset, Useful Life				10 years
FSC Holdings, LLC [Member] \| Minimum [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Finite-Lived Intangible Asset, Useful Life				7 years

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	$ 67,909	$ 47,309
Amortizable intangible assets: Accumulated Amortization	(38,700)	(31,484)
Amortizable intangible assets: Net Carrying Value	29,209	15,825
Unamortizable intangible assets: Goodwill, Gross	18,669	18,491
Unamortizable intangible assets:Accumulated Amortization	0	0
Unamortizable intangible assets: Net Carrying Value	18,669	18,491
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Unamortizable intangible assets: Goodwill, Gross	18,669	18,491
Unamortizable intangible assets:Accumulated Amortization	0	0
Unamortizable intangible assets: Net Carrying Value	18,669	18,491
Product marketing rights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	16,200	0
Amortizable intangible assets: Accumulated Amortization	(750)	0
Amortizable intangible assets: Net Carrying Value	15,450	0
Developed Technology Rights [Member] \| Flexichamber Member
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	4,400	0
Amortizable intangible assets: Accumulated Amortization	(183)	0
Amortizable intangible assets: Net Carrying Value	4,217	0
Developed Technology Rights [Member] \| Vazculep [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	12,061	12,061
Amortizable intangible assets: Accumulated Amortization	(8,394)	(7,986)
Amortizable intangible assets: Net Carrying Value	3,667	4,075
Developed Technology Rights [Member] \| Bloxiverz [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	35,248	35,248
Amortizable intangible assets: Accumulated Amortization	(29,373)	(23,498)
Amortizable intangible assets: Net Carrying Value	$ 5,875	$ 11,750

Goodwill and Intangible Assets (Details 1) $ in Thousands	Jun. 30, 2016 USD ($)
Finite-Lived Intangible Assets [Line Items]
2016	$ 14,616
2017	3,056
2018	3,056
2019	3,056
2020	3,056
Total	$ 26,840

Goodwill and Intangible Assets (Details 2) $ in Thousands	6 Months Ended
Goodwill and Intangible Assets (Details 2) $ in Thousands	Jun. 30, 2016 USD ($)
Goodwill [Line Items]
Balance, Beginning	$ 18,491
Impact of FSC acquisition	178
Balance, Ending	$ 18,669

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 3,702	$ 3,139	$ 7,216	$ 6,282	$ 7,171

Long-Term Related Party Payable (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

$ 122,693

Additions

22,695

Payments to Related Parties

(16,315)

Operating Expense; Acquisition-Related

$ 23,898

$ 32,000

32,141

$ 37,254

Interest Expense; Financing-Related

4,307

Less: Current portion

(29,500)

$ (25,204)

Total long-term related party payable

136,021

$ 97,489

Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Ending

165,521

Warrant [Member] | Acquisition-related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[1]

20,617

Additions

^[1]

Payments to Related Parties

^[1]

Operating Expense; Acquisition-Related

^[1]

(5,155)

Interest Expense; Financing-Related

^[1]

Business Combination,Ending

^[1]

15,462

Earn Out Payments [Member] | Acquisition-related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[2]

90,468

Additions

^[2]

Payments to Related Parties

^[2]

(14,216)

Operating Expense; Acquisition-Related

^[2]

38,362

Interest Expense; Financing-Related

^[2]

Business Combination,Ending

^[2]

114,614

Deerfield Royalty agreement [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[3]

7,862

Additions

^[3]

Payments to Related Parties

^[3]

(1,337)

Operating Expense; Acquisition-Related

^[3]

Interest Expense; Financing-Related

^[3]

2,915

Business Combination,Ending

^[3]

9,440

Broadfin Royalty agreement [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[4]

3,746

Additions

^[4]

Payments to Related Parties

^[4]

(638)

Operating Expense; Acquisition-Related

^[4]

Interest Expense; Financing-Related

^[4]

1,392

Business Combination,Ending

^[4]

4,500

FSC Royalty Agreement [Member] | Acquisition-related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[5]

Additions

^[5]

7,695

Payments to Related Parties

^[5]

(124)

Operating Expense; Acquisition-Related

^[5]

(1,066)

Interest Expense; Financing-Related

^[5]

Business Combination,Ending

^[5]

6,505

FSC Long term Liability [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[6]

Additions

^[6]

15,000

Payments to Related Parties

^[6]

Operating Expense; Acquisition-Related

^[6]

Interest Expense; Financing-Related

^[6]

Business Combination,Ending

^[6]

$ 15,000

[1]	As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.
[2]	In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
[3]	As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.
[4]	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
[5]	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.
[6]	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000.

Long-Term Related Party Payable (Details 1) - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
Weighted average exercise price per share	$ 8.63	$ 8.63
Expected term (years)	1 year 9 months	2 years 9 months
Expected volatility	69.70%	62.90%
Risk-free interest rate	0.55%	0.92%
Expected dividend yield	0.00%	0.00%

Long-Term Related Party Payable (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended			6 Months Ended	12 Months Ended
	Jan. 31, 2021	Feb. 29, 2016	Feb. 28, 2013	Jun. 30, 2016	Dec. 31, 2013	Mar. 31, 2012
Line of Credit Facility [Line Items]
Cash Consideration Received On Royalty Agreement			$ 2,600		$ 2,200
Percentage Of Royalty Payable On Net Sales			1.75%		0.834%
Payments to Acquire Businesses, Gross				$ 16,315
Minimum [Member]
Line of Credit Facility [Line Items]
Discounted Cash Flow Risk Adjusted Discount Rate				15.00%
Maximum [Member]
Line of Credit Facility [Line Items]
Discounted Cash Flow Risk Adjusted Discount Rate				32.00%
Eclat Pharmaceuticals [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						3,300
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1,100
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 11.00
FSC Holdings, LLC [Member]
Line of Credit Facility [Line Items]
Percentage Of Royalty Payable On Net Sales		15.00%
Royalty Amount		$ 12,500
Payments to Acquire Businesses, Gross		$ 1,050
FSC Holdings, LLC [Member] \| Scenario, Forecast [Member]
Line of Credit Facility [Line Items]
Final Payments to Acquire Business Gross	$ 15,000
Exercise Price 1 [Member] \| Eclat Pharmaceuticals [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						2,200
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 7.44

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Taxes [Line Items]
Income (loss) before income taxes	$ (12,509)	$ (8,351)	$ (11,255)	$ 13,569
United States [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	(2,187)	4,050	11,762	20,773
France [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	(2,288)	(1,123)	(9,089)	9,113
Ireland [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	$ (8,034)	$ (11,278)	$ (13,928)	$ (16,317)

Income Taxes (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details 1) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Taxes [Line Items]
Statutory tax rate	33.30%	33.30%	33.30%	33.30%
International tax rates differential	(13.20%)	(31.80%)	(27.70%)	27.60%
Valuation allowance on net operating losses	(11.90%)	(16.00%)	(34.80%)	2.40%
Nondeductible contingent consideration	(64.20%)	(132.30%)	(96.00%)	90.90%
Nondeductible stock-based compensation	(1.70%)	38.90%	(3.90%)	(26.40%)
Deferred charge from IP transfer	0.00%	(0.20%)	(4.40%)	0.50%
State and local income taxes	(2.80%)	(1.60%)	(4.20%)	1.90%
Other	0.90%	8.00%	6.40%	(3.40%)
Effective income tax rate	(59.50%)	(101.90%)	(131.20%)	126.90%
Income tax provision - at Statutory tax rate	$ (4,165)	$ (2,781)	$ (3,748)	$ 4,518
International tax rates differential	1,647	2,658	3,115	3,748
Valuation allowance on net operating losses	1,485	1,338	3,913	332
Nondeductible contingent consideration	8,029	11,049	10,800	12,329
Nondeductible stock-based compensation	216	(3,246)	434	(3,579)
Deferred charge from IP transfer	(1)	17	493	69
State and local income taxes	356	136	477	255
Other	(118)	(664)	(723)	(458)
Income tax provision - at Effective income tax rate	$ 7,449	$ 8,507	$ 14,761	$ 17,214

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$ 7,449	$ 8,507	$ 14,761	$ 17,214

Other Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Prepaid expenses and other current assets
Valued-added tax recoverable	$ 1,216	$ 1,099
Prepaid expenses	3,457	2,921
Advance to suppliers and other current assets	1,604	518
Income tax receivable	3,380	3,526
Total	$ 9,657	$ 8,064

Other Assets and Liabilities (Details 1) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Prepaid Expenses And Other Current Assets [Line Items]
Deferred tax assets	$ 5,542	$ 0
Other	119	167
Total	$ 5,661	$ 167

Other Assets and Liabilities (Details 2) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Expenses [Line Items]
Accrued compensation	$ 2,383	$ 1,888
Accrued social charges	1,132	1,710
Accrued trade discounts and rebates	6,914	5,710
Other	163	0
Total	$ 10,592	$ 9,308

Other Assets and Liabilities (Details 3) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Other Current And Long Term Liabilities [Line Items]
Valued-added tax payable	$ 185	$ 0
Other	479	133
Total	$ 664	$ 133

Other Assets and Liabilities (Details 4) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Other Current And Long Term Liabilities [Line Items]
Provision for retirement indemnity	$ 2,274	$ 2,170
Other	597	356
Total	$ 2,871	$ 2,526

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Line Items]
Net loss	$ (19,958)	$ (16,858)	$ (26,016)	$ (3,645)
Weighted average shares:
Basic shares	41,241	40,353	41,241	40,281
Effect of dilutive securities—options and warrants outstanding	$ 0	$ 0	$ 0	$ 0
Diluted shares	41,241	40,353	41,241	40,281
Effect of dilutive securities:
Income (loss) before income taxes	$ (0.48)	$ (0.42)	$ (0.63)	$ (0.09)
Net loss per share - diluted	$ (0.48)	$ (0.42)	$ (0.63)	$ (0.09)

Net Loss Per Share (Details Textual) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,596	6,596	6,634	6,634

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Class of Stock [Line Items]
Foreign currency translation adjustment Income (Loss), Net, Beginning Balance	$ (17,495)	$ (23,874)	$ (22,312)	$ (7,225)
Foreign currency translation adjustment Income (Loss), Net, Balance, Other comprehensive income (loss)	(2,457)	5,262	2,360	(11,387)
Foreign currency translation adjustment Income (Loss), Net, Ending Balance	(19,952)	(18,612)	(19,952)	(18,612)
Unrealized gain (loss) on marketable securities, net, Beginning Balance	574	158	(345)	(198)
Unrealized gain (loss) on marketable securities, net, Ending Balance	1,102	(198)	1,102	(198)
Unrealized gain (loss) on marketable securities, net of ($73), $0, ($158), $0 tax	528	(356)	1,447	0
Accumulated Other Comprehensive Loss at June 30	$ (18,850)	$ (18,810)	$ (18,850)	$ (18,810)	$ (22,657)

Comprehensive Income (Loss) (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	$ (73)	$ 0	$ (158)	$ 0

Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Shareholders' Equity (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Class of Stock [Line Items]
Shareholders' equity - January 1			$ 69,134
Net loss	$ (19,958)	$ (16,858)	(26,016)	$ (3,645)
Other comprehensive income	(1,929)	$ 4,906	3,807	(11,387)
Stock-based compensation expense			4,913	$ 4,152
Shareholders' equity - June 30	$ 51,838		$ 51,838

Company Operations by Product (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Company Operations by Product [Line Items]
Total product sales and services	$ 38,165	$ 48,602	$ 73,518	$ 81,128
License and research revenue	693	0	1,556	0
Total revenues	38,858	48,602	75,074	81,128
Bloxiverz [Member]
Company Operations by Product [Line Items]
Total product sales and services	25,620	44,283	50,367	72,726
Vazculep [Member]
Company Operations by Product [Line Items]
Total product sales and services	10,421	3,627	19,827	7,151
Other [Member]
Company Operations by Product [Line Items]
Total product sales and services	$ 2,124	$ 692	$ 3,324	$ 1,251